Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) and TP-6076 Data at IDWeek 2018
September 19 2018 - 6:00AM
– Four Abstracts Selected for Poster
Presentations –
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical
company focused on developing and commercializing novel antibiotics
to treat life-threatening multidrug-resistant (MDR) infections,
today announced it will have four posters and one oral presentation
at the Infectious Disease Society of America’s (IDSA) Infectious
Disease Week (IDWeek) 2018, taking place October 3-7 in San
Francisco, CA at the Moscone Center. Presentations will include
data on XERAVA™ (eravacycline), the Company’s U.S. Food and
Drug Administration approved treatment for complicated
intra-abdominal infections (cIAI), which is also under review for
regulatory approval by the European Commission for the treatment of
cIAI. Additional data will be presented on TP-6076, the Company’s
second-generation candidate to target MDR Gram-negative bacteria,
which is currently in Phase 1 clinical testing.
The details for the data presentations at IDWeek are as
follows:
XERAVA Poster Presentations
Poster title: Pooled Analysis of Safety Data
from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in
Complicated Intra-Abdominal InfectionsDate and
time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m.
PTLocation: S Poster HallPoster
number: 1976Session information:
Poster Abstract Session: Clinical Trials
Poster title: Efficacy of Eravacycline in
Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 Studies of
Complicated Intra-Abdominal InfectionsDate and
time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m.
PTLocation: S Poster HallPoster
number: 1978Session information:
Poster Abstract Session: Clinical Trials
Poster title: Combined Microbiological Response
Rates from Two Phase 3 Trials Demonstrating the Activity of
Eravacycline in the Treatment of Complicated Intra-Abdominal
Infections: A Pooled Analysis of IGNITE1 and IGNITE4Date
and time: Saturday, October 6 from 12:30 p.m. – 1:45 p.m.
PTLocation: S Poster HallPoster
number: 1963Session information:
Poster Abstract Session: Clinical Trials
TP-6076 Oral Presentation
Presentation title: TP-6076 – Tetraphase
PharmaceuticalsDate and time: Thursday, October 4
from 2:00 p.m. – 3:15 p.m. PTLocation: N Hall
DPresentation number: 837Speaker:
Larry Tsai, M.D. Session information: Exploring
the Antibiotic Pipeline 2018
TP-6076 Poster Presentation
Poster title: Safety, Tolerability and
Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully
Synthetic Tetracycline, in a Phase 1 StudyDate and
time: Friday, October 5 from 12:30 p.m. – 1:45 p.m.
PTLocation: S Poster HallPoster
number: 1371Session information: Poster
Abstract Session: Novel Agents
Additional Activities
- Tetraphase will host a XERAVA exhibit booth (#324) at IDWeek
2018 during exhibit hours: Thursday, October 4; from 11:45 a.m. –
6:00 p.m. PT; Friday, October 5 from 10:00 a.m. – 4:00 p.m. PT; and
Saturday, October 6 from 10:00 a.m. – 2:00 p.m. PT. Tetraphase
Medical Affairs also will be present at booth #322 during exhibit
hours.
- Tetraphase has provided an independent educational grant in
support of a Continuing Medical Education Lunch Symposium entitled
“Emerging Options for Complicated Gram-Negative Infections:
Considerations for Intra-Abdominal and Urinary Tract Infections.”
It will take place on Wednesday, October 3, from 11:00 a.m. – 1:00
p.m. PT at Moscone South 206-208.
IDWeek is the combined annual meeting of the Infectious Diseases
Society of America (IDSA), the Society for Healthcare Epidemiology
of America (SHEA), the HIV Medicine Association (HIVMA), and the
Pediatric Infectious Diseases Society (PIDS). Full abstracts can be
found on the IDWeek website at http://www.idweek.org/
About XERAVA™ XERAVA
(eravacycline for injection) is a tetracycline class antibacterial
indicated for the treatment of complicated intra-abdominal
infections in patients 18 years of age and older. XERAVA was
investigated for the treatment of cIAI as part of the Company's
IGNITE (Investigating
Gram-Negative
Infections Treated with
Eravacycline) phase 3 programs. In the first
pivotal phase 3 trial in patients with cIAI, twice-daily
intravenous (IV) XERAVA met the primary endpoint by demonstrating
statistical non-inferiority of clinical response compared to
ertapenem and was well-tolerated. In the second phase 3 clinical
trial in patients with cIAI, twice-daily IV XERAVA met the primary
endpoint by demonstrating statistical non-inferiority of clinical
response compared to meropenem and was well-tolerated. In both
trials, XERAVA achieved high cure rates in patients with
Gram-negative pathogens, including resistant isolates.
Important Safety Information
To report suspected adverse reactions, contact
Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282)
or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full prescribing information for XERAVA at
www.XERAVA.com.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase Pharmaceuticals, Inc., is a
biopharmaceutical company using its proprietary chemistry
technology to create novel antibiotics for serious and
life-threatening bacterial infections, including those caused by
many of the multidrug-resistant bacteria highlighted as urgent
public health threats by the World Health Organization and the
Centers for Disease Control and Prevention. The Company has created
more than 3,000 novel tetracycline compounds using its proprietary
technology platform. Tetraphase's lead product XERAVA™ is approved
for the treatment of complicated intra-abdominal infections (cIAI)
by the U.S. Food and Drug Administration and under review for
marketing application authorization approval by the European
Commission for the treatment of cIAI. The Company’s pipeline also
includes TP-271 and TP-6076, which are in phase 1 clinical trials.
Please visit www.tphase.com for more company information.
Forward-Looking StatementsAny statements in
this press release about our future expectations, plans and
prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, and other statements
containing the words "anticipates," "believes," "expects," "plans,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including whether eravacycline will be
successfully distributed and marketed and other regulatory and
commercial risk factors discussed in the "Risk Factors" section of
our quarterly report on Form 10-Q for the period ended June 30,
2018, filed with the Securities and Exchange Commission on August
2, 2018. In addition, the forward-looking statements included in
this press release represent our views as of September 19, 2018. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so.
Media and Investor Contact:Tetraphase
PharmaceuticalsJennifer Viera617-600-7040jviera@tphase.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Jul 2023 to Jul 2024